title: Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis.
abstract: Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil(®)) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (p < 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.
authors.affiliation: Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.|Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands.
authors.forename: Robin E A
authors.initials: RE
authors.lastname: Tjon Pian Gi
authors.affiliation: Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.|Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands.
authors.forename: Michel R M
authors.initials: MR
authors.lastname: San Giorgi
authors.affiliation: Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center, Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.affiliation: Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center, Heidelberg, Germany.
authors.forename: Angelika
authors.initials: A
authors.lastname: Michel
authors.affiliation: Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Bettien M
authors.initials: BM
authors.lastname: van Hemel
authors.affiliation: Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.|Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands.
authors.forename: Ed M D
authors.initials: EM
authors.lastname: Schuuring
authors.affiliation: Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, The Netherlands.
authors.forename: Edwin R
authors.initials: ER
authors.lastname: van den Heuvel
authors.affiliation: Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.|Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands.
authors.forename: Bernard F A M
authors.initials: BF
authors.lastname: van der Laan
authors.affiliation: Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. f.g.dikkers@umcg.nl.|Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands. f.g.dikkers@umcg.nl.
authors.forename: Frederik G
authors.initials: FG
authors.lastname: Dikkers
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000601:surgery; D012044:Regression Analysis; D012141:Respiratory Tract Infections / Q000517:prevention & control* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D000914:Antibodies, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
keywords: Immunology; Recurrent respiratory papillomatosis; Therapeutic drug; Vaccine